In this video, we explore the use of alpha-2 agonists in the treatment of ADHD, specifically focusing on guanfacine ER (Intuniv) and clonidine ER (Kapvay). These non-stimulant ADHD medications have become viable options for patients who may not tolerate stimulants or have comorbid conditions that make stimulant medications less effective or problematic.
In this video, Dr. Chris Aiken, Editor-in-Chief of The Carlat Psychiatry Report, provides a comprehensive review of Gepirone, also known as Exxua, a newly FDA-approved antidepressant for major depressive disorder in adults. Gepirone is unique due to its classification as an azipirone, a class of medications that work as serotonin 5-HT1A receptor agonists.
In this video, we aim to break down where the safe upper limits lie for stimulant dosing, what to consider when increasing doses, and why crossing certain thresholds can lead to serious risks.
We start by discussing why increasing stimulant doses beyond a certain point can be dangerous.
In this episode, we explore nine groundbreaking stories in mental health and psychiatric medicine, covering everything from healthcare fraud to the latest advancements in drug trials. First, we dive into the recent charges brought by the US Department of Justice against executives at Done, a California-based telehealth company, for alleged healthcare fraud. Done is accused of prescribing over 40 million Adderall pills to patients without proper evaluation, raising concerns about the balance between increasing mental healthcare access and responsible prescribing practices.
In this video, we explore the potential of L-Methylfolate as a vital supplement in depression treatment. L-Methylfolate is a form of folate, a naturally occurring B-vitamin, and is often used to enhance the effects of traditional antidepressants.
In this video, we explore the latest breakthroughs in antidepressant augmentation, showing how personalized medicine can enhance outcomes for patients with various forms of depression. Whether your patient is facing anxious depression, depression with insomnia, or psychotic depression, this video offers evidence-based strategies that incorporate augmenation options such as lithium for depression, esketamine for depression, and quetiapine for depression.
Vilazodone, also known by its brand name Viibryd, became available as a generic in June 2022 after 11 years of market exclusivity. With the introduction of the Viibryd generic, the price of this multimodal antidepressant has significantly decreased, making it more accessible. However, the critical question remains: is vilazodone worth prescribing?
This video breaks down the findings from a meta-analysis of randomized controlled trials, examining how aripiprazole dosage impacts patient outcomes in clinical depression treatment.
We’re taking a deep dive into Auvelity, a new antidepressant that combines Dextromethorphan and Bupropion. While Bupropion is well-established in the treatment of depression, Dextromethorphan is less familiar in psychiatric contexts.
In today’s video, we explore the off-label uses of Gabapentin, also known as Neurontin. While Gabapentin is FDA-approved for partial seizures and postherpetic neuralgia, its off-label uses are more extensive, especially in psychiatry.
KarXT (Cobenfy) is the first antipsychotic that doesn’t block dopamine. We trace the origins of this new drug to a South Asian herb used for over 5,000 years, up to the three...